Literature DB >> 20817518

Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease.

Jan Korabecny1, Kamil Musilek, Ondrej Holas, Jiri Binder, Filip Zemek, Jan Marek, Miroslav Pohanka, Veronika Opletalova, Vlastimil Dohnal, Kamil Kuca.   

Abstract

All approved drugs for Alzheimer disease (AD) in clinical practice ameliorate the symptoms of the disease. Among them, acetylcholinesterase inhibitors (AChEIs) are used to increase the cholinergic activity. Among new AChEI, tacrine compounds were found to be more toxic compared to 7-MEOTA (9-amino-7-methoxy-1,2,3,4-tetrahydroacridine). In this Letter, series of 7-MEOTA analogues (N-alkyl-7-methoxytacrine) were synthesized. Their inhibitory ability was evaluated on recombinant human acetylcholinesterase (AChE) and plasmatic human butyrylcholinesterase (BChE). Three novel compounds showed promising results towards hAChE better to THA or 7-MEOTA. Three compounds resulted as potent inhibitors of hBChE. The SAR findings highlighted the C(6)-C(7)N-alkyl chains for cholinesterase inhibition.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20817518     DOI: 10.1016/j.bmcl.2010.08.044

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  7 in total

1.  In Vitro Effects of Cognitives and Nootropics on Mitochondrial Respiration and Monoamine Oxidase Activity.

Authors:  Namrata Singh; Jana Hroudová; Zdeněk Fišar
Journal:  Mol Neurobiol       Date:  2016-09-23       Impact factor: 5.590

2.  New acetylcholinesterase inhibitors for Alzheimer's disease.

Authors:  Mona Mehta; Abdu Adem; Marwan Sabbagh
Journal:  Int J Alzheimers Dis       Date:  2011-12-15

3.  Synthesis and in vitro evaluation of N-(Bromobut-3-en-2-yl)-7-methoxy-1,2,3,4-tetrahydroacridin-9-amine as a cholinesterase inhibitor with regard to Alzheimer's disease treatment.

Authors:  Jan Korabecny; Kamil Musilek; Ondrej Holas; Eugenie Nepovimova; Daniel Jun; Filip Zemek; Veronika Opletalova; Jiri Patocka; Vlastimil Dohnal; Florian Nachon; Jana Hroudova; Zdenek Fisar; Kamil Kuca
Journal:  Molecules       Date:  2010-12-02       Impact factor: 4.411

4.  Development of 2-Methoxyhuprine as Novel Lead for Alzheimer's Disease Therapy.

Authors:  Eva Mezeiova; Jan Korabecny; Vendula Sepsova; Martina Hrabinova; Petr Jost; Lubica Muckova; Tomas Kucera; Rafael Dolezal; Jan Misik; Katarina Spilovska; Ngoc Lam Pham; Lucia Pokrievkova; Jaroslav Roh; Daniel Jun; Ondrej Soukup; Daniel Kaping; Kamil Kuca
Journal:  Molecules       Date:  2017-07-28       Impact factor: 4.411

Review 5.  Merged Tacrine-Based, Multitarget-Directed Acetylcholinesterase Inhibitors 2015-Present: Synthesis and Biological Activity.

Authors:  Todd J Eckroat; Danielle L Manross; Seth C Cowan
Journal:  Int J Mol Sci       Date:  2020-08-19       Impact factor: 5.923

6.  7-Methoxytacrine-adamantylamine heterodimers as cholinesterase inhibitors in Alzheimer's disease treatment--synthesis, biological evaluation and molecular modeling studies.

Authors:  Katarina Spilovska; Jan Korabecny; Jan Kral; Anna Horova; Kamil Musilek; Ondrej Soukup; Lucie Drtinova; Zuzana Gazova; Katarina Siposova; Kamil Kuca
Journal:  Molecules       Date:  2013-02-20       Impact factor: 4.411

Review 7.  Alzheimer's Disease Pharmacotherapy in Relation to Cholinergic System Involvement.

Authors:  Gabriela Dumitrita Stanciu; Andrei Luca; Razvan Nicolae Rusu; Veronica Bild; Sorin Ioan Beschea Chiriac; Carmen Solcan; Walther Bild; Daniela Carmen Ababei
Journal:  Biomolecules       Date:  2019-12-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.